Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis
- PMID: 1003098
- PMCID: PMC2190483
- DOI: 10.1084/jem.144.6.1424
Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis
Abstract
The acidic tetrapeptides of ECF-A, Ala/Val-Gly-Ser-Glu, exhibit peak in vitro chemotactic activity for human eosinophils at concentrations of 3 X 10(-8) M to 10(-6) M, and rapidly deactivate eosinophils to homologous and other stimuli at concentrations as low as 10(-10) M. The analogue Leu-Gly-Ser-Glu reaches peak activity at 10(-8)M-10(-7)M, while Phe-Gly-Ser-Glu requires 10(-4)M to elicit a peak response. Although inversion of the order of glycine and serine does not alter the eosinophil chemotactic activity of the tetrapeptides, deletion of glycine increases by 10-fold the concentration required for peak chemotactic activity, indicating the critical nature of the spacing between NH2- and COOH-terminal residues. The substituent COOH-terminal tripeptide, which is only marginally chemotactic, irreversibly suppresses eosinophil chemotactic responsiveness at a concentration 10,000-fold higher than concentrations necessary for deactivation by the intact tetrapeptide. The high concentration of tripeptide required for this cell directed effect, which is assumed to be analogous to deactivation, is attributed to the absence of the NH2-terminal residue which would facilitate effective interaction with the eosinophil. A substituent NH2-terminal tripeptide and amides of the NH2-terminal amino acids, which are devoid of chemotactic and deactivating activities, reversibly inhibit the tetrapeptide stimulus in a dose-response fashion. The additional finding that the NH2-terminal tripeptide protects the eosinophil from deactivation by the intact tetrapeptide confirms that the competitive interaction is stimulus specific.
Similar articles
-
Tetrapeptides of the eosinophil chemotactic factor of anaphylaxis (ECF-A) enhance eosinophil Fc receptor.Nature. 1981 Jan 1;289(5793):71-3. doi: 10.1038/289071a0. Nature. 1981. PMID: 7453810
-
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis.Proc Natl Acad Sci U S A. 1975 Oct;72(10):4123-7. doi: 10.1073/pnas.72.10.4123. Proc Natl Acad Sci U S A. 1975. PMID: 1060093 Free PMC article.
-
A chemotactic receptor for val(ala)-gly-ser-glu on human.Immunol Commun. 1976;5(6):469-79. doi: 10.3109/08820137609033861. Immunol Commun. 1976. PMID: 992702
-
Modulation of human eosinophil polymorphonuclear leukocyte migration and function.Am J Pathol. 1976 Nov;85(2):419-36. Am J Pathol. 1976. PMID: 793410 Free PMC article. Review.
-
Eosinophil chemotactic factor of anaphylaxis (ECF-A): cellular origin, structure and function.Monogr Allergy. 1977;12:189-97. Monogr Allergy. 1977. PMID: 335214 Review. No abstract available.
Cited by
-
Specific inhibition of the polymorphonuclear leukocyte chemotactic response to hydroxy-fatty acid metabolites of arachidonic acid by methyl ester derivatives.J Clin Invest. 1979 Jun;63(6):1181-6. doi: 10.1172/JCI109412. J Clin Invest. 1979. PMID: 447841 Free PMC article.
-
Chemotactic peptides. Mechanisms, functions, and possible role in inflammatory bowel disease.Dig Dis Sci. 1988 Mar;33(3 Suppl):50S-57S. doi: 10.1007/BF01538131. Dig Dis Sci. 1988. PMID: 3278869 Review.
-
The functional and physicochemical characterization of three eosinophilotactic activities released into the circulation by cold challenge of patients with cold urticaria.Clin Exp Immunol. 1982 Mar;47(3):570-8. Clin Exp Immunol. 1982. PMID: 7083632 Free PMC article.
-
Effect of aminoglycosides on the chemotactic response of human polymorphonuclear leukocytes.Antimicrob Agents Chemother. 1977 Oct;12(4):540-42. doi: 10.1128/AAC.12.4.540. Antimicrob Agents Chemother. 1977. PMID: 921250 Free PMC article.
-
Cold urticaria. Recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge.J Clin Invest. 1977 Jul;60(1):189-96. doi: 10.1172/JCI108756. J Clin Invest. 1977. PMID: 874083 Free PMC article.